These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12394255)

  • 21. Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
    Esteban E; Modollel A; González de Sande L; Palacio I; Muñiz I; Fernández Y; Corral N; Fra J; Sala M; Vieitez JM; Estrada E; Lacave AJ;
    Breast Cancer Res Treat; 2003 Aug; 80(3):257-65. PubMed ID: 14503798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
    Fabi A; Papaldo P; Pino MS; Ferretti G; Carlini P; Pacetti U; Di Cosimo S; Nardoni C; Giannarelli D; Sacchi I; Cognetti F
    Anticancer Res; 2004; 24(3b):1963-7. PubMed ID: 15274385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
    Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
    J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
    Mavroudis D; Alexopoulos A; Malamos N; Ardavanis A; Kandylis C; Stavrinidis E; Kouroussis Ch; Agelaki S; Androulakis N; Bozionelou V; Georgoulias V
    Oncology; 2003; 64(3):207-12. PubMed ID: 12697959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
    Airoldi M; Cattel L; Pedani F; Marchionatti S; Tagini V; Bumma C; Recalenda V
    Acta Oncol; 2003; 42(3):186-94. PubMed ID: 12852694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
    Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
    Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
    Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
    J Clin Oncol; 1999 Mar; 17(3):862-9. PubMed ID: 10071277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
    Di Lauro L; Belli F; Arena MG; Carpano S; Paoletti G; Giannarelli D; Lopez M
    Ann Oncol; 2005 Sep; 16(9):1498-502. PubMed ID: 15956036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
    Morales S; Lorenzo A; Ramos M; Ballesteros P; Méndez M; Almanza C; Castellanos J; Moreno-Nogueira JA; Casal J; Lizón J; Oltra A; Frau A; Machengs I; Galán A; Belón J; Llorca C
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):75-81. PubMed ID: 14557896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer.
    Gamucci T; D'Ottavio AM; Magnolfi E; Barduagni M; Vaccaro A; Sperduti I; Moscetti L; Belli F; Meliffi L
    Br J Cancer; 2007 Oct; 97(8):1040-5. PubMed ID: 17940499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer.
    Alexopoulos A; Karamouzis MV; Stavrinides H; Ardavanis A; Kandilis K; Stavrakakis J; Georganta C; Rigatos G
    Ann Oncol; 2004 Jun; 15(6):891-5. PubMed ID: 15151945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
    Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
    Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
    Mavroudis D; Saloustros E; Boukovinas I; Papakotoulas P; Kakolyris S; Ziras N; Christophylakis C; Kentepozidis N; Fountzilas G; Rigas G; Varthalitis I; Kalbakis K; Agelaki S; Hatzidaki D; Georgoulias V
    Br J Cancer; 2017 Jul; 117(2):164-170. PubMed ID: 28641315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
    Aihara T; Takatsuka Y; Itoh K; Sasaki Y; Katsumata N; Watanabe T; Noguchi S; Horikoshi N; Tabei T; Sonoo H; Hiraki S; Inaji H
    Oncology; 2003; 64(2):124-30. PubMed ID: 12566909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.